Max Klement is a Principal at BGV having joined the company in 2019.
Max has prior experience in startups and in larger biotech organizations. At JHL Biotech, a biosimilars and contract manufacturing company, he led the Process Development Team and was a Project Manager for novel and biosimilar biologics. Prior to JHL Biotech, Max was a founding team member at Hummingbird Bioscience where he was a Project Manager for Pharmaceutical and Academic collaborations in gastric and liver cancer. Max holds a Ph.D. from the National University of Singapore as an A*STAR fellow where he worked in the lab of Prof. Miranda Yap on antibody engineering approaches, which culminated in a commercial out-licensing agreement. Max completed his MBA from INSEAD in 2018.
Max was part of the deal team for a number of the BGV IV investments including dualyx, VectorY, Fibrocor, and most notably, the company creation of Complement Therapeutics.
MSc Chemical and Biomolecular Engineering
PhD Chemical and Biomolecular Engineering